Journal of Allergy and Clinical Immunology: Global (May 2024)

Exploring gastric cancer genetics: A turning point in common variable immunodeficiency

  • Silvia Sánchez-Ramón, MD, PhD,
  • Jesús Fuentes-Antrás, MD,
  • Nicholas L. Rider, MD,
  • Pedro Pérez-Segura, MD, PhD,
  • Eduardo de la Fuente-Muñoz, MD,
  • Miguel Fernández-Arquero, PhD,
  • Esmeralda Neves, MD,
  • Rebeca Pérez de Diego, PhD,
  • Alberto Ocaña, MD, PhD,
  • Kissy Guevara-Hoyer, MD, PhD

Journal volume & issue
Vol. 3, no. 2
p. 100203

Abstract

Read online

Background: Gastric cancer (GC) stands as a prominent cause of cancer-related mortality and ranks second among the most frequently diagnosed malignancies in individuals with common variable immunodeficiency (CVID). Objective: We sought to conduct a comprehensive, large-scale genetic analysis to explore the CVID-associated germline variant landscape within gastric adenocarcinoma samples and to seek to delineate the transcriptomic similarities between GC and CVID. Methods: We investigated the presence of CVID-associated germline variants in 1591 GC samples and assessed their impact on tumor mutational load. The progression of GC was evaluated in patients with and without these variants. Transcriptomic similarities were explored by matching differentially expressed genes in GC to healthy gastric tissue with a CVID transcriptomic signature. Results: CVID-associated germline variants were found in 60% of GC samples. Our analysis revealed a significant association between the presence of CVID-related genetic variants and higher tumor mutational load in GC (P < .0001); high GC mutational load seems to be linked to immunotherapy response and worse prognosis. Transcriptomic similarities unveiled key genes and pathways implicated in innate immune responses and tumorigenesis. We identified upregulated genes related to oncogene drivers, inflammation, tumor suppression, DNA repair, and downregulated immunomodulatory genes shared between GC and CVID. Conclusions: Our findings contribute to a deeper understanding of potential molecular modulators of GC and shed light on the intricate interplay between immunodeficiency and cancer. This study underscores the clinical relevance of CVID-related variants in influencing GC progression and opens avenues for further exploration into novel therapeutic approaches.

Keywords